iBio, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2022; filed October 11, 2022. The requested “2021 Q4” period does not match the filing, which is an annual report for fiscal 2022.
Business Context
iBio develops biopharmaceuticals using its AI-driven discovery platform, FastPharming plant-based manufacturing system, and Glycaneering technologies. It operates two segments: Biopharmaceuticals and Bioprocessing, the latter providing contract development and manufacturing services from a 130,000-square-foot Texas facility.
All proprietary vaccine and therapeutic candidates remained in preclinical development. The company’s strategic focus was shifting toward AI-enabled immuno-oncology discovery and development while evaluating measures to extend its cash runway.
Key Financial Metrics
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $2.383 million | $2.371 million | Up approximately 1% |
| Gross profit | $2.167 million | $0.909 million | Higher primarily due to lower cost of goods sold |
| Research and development expense | $17.729 million | $9.989 million | Up 77% |
| General and administrative expense | $34.128 million | $22.031 million | Up 55% |
| Operating loss | $49.690 million | $31.111 million | Worsened |
| Net loss attributable to iBio stockholders | $50.391 million | $23.467 million | Worsened |
| Loss per share | $5.78 | $3.00 | Worsened |
| Net cash used in operating activities | $37.480 million | $30.064 million | Higher cash burn |
| Cash, cash equivalents and investments in debt securities | $39.5 million | Not clearly provided as a comparable aggregate | |
| Accumulated deficit | $223.930 million | $173.627 million | Increased |
Revenue consisted of $1.8 million of Fraunhofer license revenue and $0.583 million of CDMO services revenue. The company stated that CDMO services revenue was approximately $2.4 million in both fiscal years before the license revenue and other timing effects.
At June 30, 2022, total assets were $99.406 million, total liabilities were $35.921 million, and stockholders’ equity was $63.485 million. Current assets were $45.070 million versus current liabilities of $30.436 million.
Debt and Liquidity
- iBio CDMO entered into a $22.375 million secured term loan in connection with the purchase of the Texas facility. The loan bears interest at 3.25% and was originally scheduled to mature on November 1, 2023.
- The term loan was secured by the facility and substantially all iBio CDMO assets, and iBio guaranteed the obligations.
- On October 11, 2022, the credit agreement was amended to require a $5.5 million principal payment, a $5.1 million payment from the next Fraunhofer settlement receipt, and $250,000 monthly principal payments for six months through March 2023.
- The amended liquidity covenant required at least $7.5 million of unrestricted cash, with a potential reduction to $5.0 million upon satisfaction of a specified milestone. Management stated that failure to extend the cash runway could result in covenant violation on December 31, 2022.
- Management and the auditor reported substantial doubt regarding the company’s ability to continue as a going concern. Management stated that available cash and investments were not expected to support operations beyond the third quarter of fiscal 2023 without reduced spending or additional capital.
Material Changes Versus the Prior Period
- Revenue was broadly stable, but the mix shifted substantially toward $1.8 million of Fraunhofer license revenue while CDMO services revenue declined.
- R&D expense increased by $7.7 million due primarily to higher personnel, consulting, outside services, and pipeline-development costs.
- G&A expense increased by $12.1 million, including higher personnel and facility costs and a $1.8 million impairment of the RubrYc equity investment.
- The fiscal 2021 results included $10.2 million of Fraunhofer settlement income; no comparable settlement income was recorded in fiscal 2022.
- In November 2021, iBio acquired the Texas manufacturing facility and the remaining interest in iBio CDMO for total consideration of $28.75 million, funded principally with cash and secured debt.
- On September 19, 2022, after year-end, iBio acquired substantially all RubrYc assets, including an AI drug discovery platform, IBIO-101, three immuno-oncology candidates, and a PD-1 agonist. Consideration included approximately $1 million of common stock and potential milestone payments of up to $5 million.
- On October 7, 2022, the company effected a one-for-twenty-five reverse stock split; all reported share and per-share amounts were retroactively adjusted.
Pipeline, Outlook, and Risks
- IBIO-101 was identified as the lead immuno-oncology asset. Management anticipated moving it from IND-enabling work toward an IND filing during calendar 2024, subject to funding and development progress.
- IBIO-202, a COVID-19 vaccine candidate, showed no protective effect in an IND-enabling animal challenge study at any of five tested dose levels. The company decided not to proceed with an IND submission in 2023 and would reassess the program.
- Management anticipated a sequential decline in fiscal 2023 revenue and slower R&D expense growth than in fiscal 2022.
- The company was reviewing cost reductions, pipeline prioritization, asset sales or licenses, partnerships, grants, non-dilutive funding, and equity financing to extend liquidity.
- Major risks include continued operating losses, dependence on additional financing, debt covenant compliance, potential dilution, preclinical and regulatory failure, customer concentration, limited CDMO utilization, supply-chain disruption, dependence on a single manufacturing facility, intellectual-property challenges, COVID-19 effects, and NYSE American listing compliance.
- Fiscal 2022 revenue was highly concentrated: one customer represented 76% of revenue, primarily from the Fraunhofer license arrangement.
Investor Verification Checklist
- Verify the company’s subsequent liquidity position, financing activity, and compliance with the amended Woodforest credit agreement.
- Confirm whether the required $5.5 million and Fraunhofer-related $5.1 million debt payments were made and whether the liquidity covenant was satisfied.
- Assess the actual post-year-end cash runway against management’s going-concern disclosure.
- Review the accounting, valuation, and integration of the RubrYc asset acquisition and the potential $5 million milestone obligations.
- Track IBIO-101’s IND-enabling progress and the company’s revised plans for IBIO-202, IBIO-100, and IBIO-400.
- Evaluate the sustainability of CDMO revenue, customer concentration, facility utilization, and the stated expectation of lower fiscal 2023 revenue.
- Review dilution from the at-the-market offering, equity compensation, reverse stock split, warrants, and any future capital raises.